Harrow Health, Inc. Q2 2026 Earnings Recap

Harrow shares fell 3.3% following results that disappointed investors due to lighter-than-expected first-half revenue and cautious outlook on second-half growth, despite management’s emphasis on improving fundamentals and multiple growth initiatives.

Key Takeaways

• First-half revenue was approximately $115 million, below initial expectations primarily due to a negative VEVYE net revenue impact.
• VEVYE prescriptions increased 21% sequentially with improved economics from revised business rules, but full commercial benefits are expected only in the second half.
• IHEEZO showed record unit demand despite losing pass-through status, with a 25% net price improvement effective July 1 and gross margins above 90%.
• Commercial investments included tripling the surgical sales team for TRIESENCE and launching Byooviz with early positive feedback; however, these remain early in ramp-up phases.
• The announced TYRVAYA acquisition is expected to modestly contribute in 2026 and strengthen the dry eye franchise long term but does not materially impact near-term results.